In the current analysis, combined Trastuzumab, alkylating agents and taxane-based chemotherapies (known in combination as ‘TCH’) formed the mainstay neoadjuvant regimen, being prescribed in excess of 85% of cases; this triple agent regimen has now become incorporated into best practice guidelines for early HER2+ breast cancer with up to T2 and/or N2 disease [37]. This evidence concerns the gene ERBB2 and breast cancer.